



Rapid Wound Healing



Jens Hansson
Executive Chairman
Mobile: +46 708 89 91 90
Mail: jens@colzyx.com



COLZYX

Revolutionizing Wound Care with Rapid Healing Technology

Chronic and infected wounds are a significant healthcare burden, affecting millions of patients globally.

Existing treatments are often slow and inadequate, leading to prolonged healing times and increased risk of complications.

Some **10-15 million patients** suffer from chronic wounds, with a total addressable market of approx.

USD 5 billion


+ additional USD 450 million market exists for animal wound care.

Standard collagen dressings and other treatments fall short in terms of speed and efficacy.

Colzyx's wound care technology accelerates the healing of infected wounds up to

4x faster

than standard collagen dressings.



Colzyx will initially target hard-to-heal wounds, however our technology is poised to broadly improve wound care treatments both in human and animal care.


Shaped by evolution to promote and protect



Colzyx utilizes human peptides **shaped by evolution** in state-of-the-art wound care products, harnessing the power of **native collagen-based technology** to promote rapid tissue repair.


Colzyx offers a **non-cytotoxic solution** for challenging tissue disruptions, **promoting cellular growth** while at the same time **preventing bacterial growth** – products that also lessen the need for using antibiotics.

Collagen VI peptides



SFV33



GVR28





Woundcom

Dermis

Fibroblast proliferation on Woundcom



Bacterial killing on Woundcom




The ultimate combination for wound healing



Unlike competitors, Woundcom uniquely **combines**

- accelerated wound healing and
- antimicrobial action

with **safe long-term use**.



* Ag+ and PHMB are classified as slightly toxic and carcinogenic, respectively.

Colzyx's peptides **kill resistant bacteria**.
Some possible **antimicrobial** applications:



Debridement tools



Implants



Catheters

Colzyx's peptides **accelerate tissue growth**.
Some possible **proliferation** applications:



Anti-scarring



Implants



Sutures

Investment opportunity



We are seeking investment to bring this groundbreaking solution to market, aiming to **dramatically improve patient outcomes** and reduce healthcare costs.

- Complete **characterization of Woundcom** to support market access submission in the **USA**.
- Submit FDA application for receiving U.S. market access through **510(k) FDA approval**.
- Launch VetCol+ in the U.S. and the E.U. **pet and equine markets**, supported by a controlled study on horse wounds. Subsequent launch into the U.S. **herd animal veterinary market**.
- Complete characterization of Colzyx's peptides to support **licensing** agreements with partners for Colzyx's **peptide platform**.
- Carry out **clinical trial** to achieve **PMA** FDA approval (U.S.) and **MDR** CE-mark (E.U.).

Revenue streams:

- Direct & partner sales – Animal wound care products (now)
- Global partnerships – Human wound care products (later)
- Out-licensing – Technology platform (soon)

Supported by a solid patent portfolio

- Three patent families
- Approved patents in Europe, USA and China